{"id":181596,"date":"2018-01-29T13:42:04","date_gmt":"2018-01-29T13:42:04","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=181596"},"modified":"2018-01-29T13:42:04","modified_gmt":"2018-01-29T13:42:04","slug":"creative-biolabs-published-a-comprehensive-review-on-cart-therapy-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biolabs-published-a-comprehensive-review-on-cart-therapy-clinical-trial_181596.html","title":{"rendered":"Creative Biolabs Published a Comprehensive Review on CAR-T Therapy Clinical Trial"},"content":{"rendered":"
Creative Biolabs, a professional biotechnology company, recently published a comprehensive review report on the global CAR T therapy clinical trial, intending to describe the present situation of the world car-t clinical research in detail.<\/div>\n

The year of 2017 is definitely one of the most important year of the field. As the CAR-T clinical trial progresses, scientists have figured out some causes of the lethal side effects of CAR-T therapy.<\/p>\n

As a breakthrough in anti-tumor therapy, CAR T technology<\/a> is still promising. According to the data from clinicatrials.gov, the number of clinical trials in each country, the biomarker targets of each trial, the indication, the current phase of each trial and the companies and institutions involved in each trial are all be discussed in the following parts.<\/p>\n

    \n
  1. Overview of the global CAR-T clinical trials<\/li>\n
  2. CAR T cell target<\/a><\/li>\n
  3. Indications<\/li>\n
  4. Phase of clinical trial<\/li>\n
  5. Companies and institutions<\/li>\n
  6. Summary and outlooks<\/li>\n<\/ol>\n

    Taking advantages of professional scientists and advanced technology platforms, Creative Biolabs has been occupied in the research of biomedical technology for more than ten years, trying to take a deep look into these CAR-T clinical trials in the detailed report. If you want to learn more knowledge about CAR-T therapy, please visit https:\/\/www.creative-biolabs.com\/car-t\/form\/car-t-clinical-trial-review.aspx<\/a>.<\/p>\n

    About Creative Biolabs <\/strong><\/p>\n

    As a global company, Creative Biolabs have more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.<\/p>\n

    Media Contact<\/span>
    Company Name:<\/strong> Creative Biolabs
    Contact Person:<\/strong> Bella Smith
    Email:<\/strong> marketing@creative-biolabs.com
    Phone:<\/strong> 1-631-830-6441
    Address:<\/strong>17 Ramsey Road
    City:<\/strong> Shirley
    State:<\/strong> New York
    Country:<\/strong> United States
    Website:<\/strong>     http:\/\/www.creativebiolabs.net<\/a><\/p>\n

    <\/object><\/p>\n

    \"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

    Creative Biolabs, a professional biotechnology company, recently published a comprehensive review report on the global CAR T therapy clinical trial, intending to describe the present situation of the world car-t clinical research in detail. The year of 2017 is definitely … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-181596","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/181596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=181596"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/181596\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=181596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=181596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=181596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}